Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis

J Comput Assist Tomogr. 2000 Mar-Apr;24(2):274-80. doi: 10.1097/00004728-200003000-00017.

Abstract

Purpose: The purpose of this work was to compare [18F]2-deoxy-2-fluoro-D-glucose (FDG) PET and 99mTc-methoxyisobutylisonitrile (MIBI) SPECT in the detection of breast cancer and axillary lymph node metastasis in the same patients.

Method: FDG-PET and MIBI-SPECT were performed within 3 days for 40 women (age range 25-86 years old) with suspected breast cancer, in whom biopsies and/or mastectomies were performed. Both images were visually assessed, and the count ratio between tumor and normal tissue (T/N ratio) was calculated.

Results: Thirty-eight patients had breast cancer, and the remaining two had benign breast lesions. The sensitivities of FDG-PET and MIBI-SPECT were 78.9 and 76.3% for breast cancer and 50.0 and 37.5% for axillary lymph node metastasis, respectively. The T/N ratio of breast cancer was significantly higher in FDG-PET (6.01 +/- 3.08 mean +/- SD) than that in MIBI-SPECT (3.48 +/- 1.21) (p = 0.01). Nonmalignant diffuse uptake of FDG in the breasts and the accumulation of MIBI in heart and liver occasionally obscured tumor uptake.

Conclusion: These results indicate that MIBI-SPECT is comparable with FDG-PET in detecting breast cancer. Neither FDG-PET nor MIBI-SPECT is sufficiently sensitive to rule out axillary lymph node metastasis.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Axilla
  • Biopsy
  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / metabolism
  • Carcinoma / diagnostic imaging*
  • Carcinoma / secondary*
  • Diagnosis, Differential
  • Female
  • Fibroadenoma / diagnostic imaging
  • Fibrocystic Breast Disease / diagnostic imaging
  • Fluorodeoxyglucose F18* / pharmacokinetics
  • Humans
  • Liver / metabolism
  • Lymphatic Metastasis
  • Mammography / methods
  • Middle Aged
  • Myocardium / metabolism
  • Predictive Value of Tests
  • Sensitivity and Specificity
  • Technetium Tc 99m Sestamibi* / pharmacokinetics
  • Tomography, Emission-Computed* / methods
  • Tomography, Emission-Computed, Single-Photon*

Substances

  • Fluorodeoxyglucose F18
  • Technetium Tc 99m Sestamibi